IT’S OFFICIAL! The S&P 500 has achieved our year-end price target of 4,750, formerly disseminated within our weekly Research Report titled “The Worst Month For Capital Returns In Focus : September 2023.” Below is the excerpt from within this report and link: “As we weigh the evidence, add up the tailwinds and headwinds, and recognize that Finom Group’s 2023 S&P 500…
The Charts, The Tables, The Quants, The Cycles
A financial market resource for the every-day investor and trader.
-
Fundstrat: Risk On To 4,500
Seth Golden, , Research Reports, 0
STRATEGY: July/August “chop” morphing into full Missouri (aka “show me state”) –> tilting us further into “risk-on” view –>...
-
The Leuthold Group: Breadth Improvement
Seth Golden, , Research Reports, 0
The Major Trend Index held at a neutral reading of zero in the week ended December 22nd. Bullish market...
-
An Uncertain Summer Ends, But Does A Favorable Fall Begin?
Seth Golden, , Research Reports, 0
In lieu of our regularly scheduled State of the Market video analysis, this week we offer a general public...
-
Weighing the impacts of a potential watershed election
Seth Golden, , Research Reports, 0
by Paul Christopher, CFA, Head of Global Market Strategy and Gary Schlossberg, Market Strategist Key takeaways We expect that...
-
Weekly State of the Market: More New Highs for 2022?
Seth Golden, , Research Reports, 0
The way Technicians feel about Fundamentals is the way Quants feel about Technicians!! Know which discipline aligns mostly with...
-
Weekly Warm-up: Technicals May Gain Upper Hand on Fundamentals if Rates Come In
Seth Golden, , Research Reports, 0
Unfortunately our monthly-cycle, weekend macro-market Research Report will be postponed until Sunday October 30, 2022, due to an unexpected...
-
Weekly State of the Market: September Getting Dicey Already?
Seth Golden, , Research Reports, 0
Keep it simple and know your ABC’s of investing: Always, Buy, Corrections!! If you would like to watch...
-
Morgan Stanley Biotechnology Team: Year-End Vaccine Probable
Seth Golden, , Research Reports, 0
Biotechnology | North America COVID-19: Increasing ConvictionMultiple Vaccine Candidates WillHave Pivotal Data Before YE20 While a pre-election result is...
Recent Articles
Featured Products
- JPM Market Recap $0.00
- JPM Research Note $0.00
- JP Morgan Market Volatility Report $0.00
Comments are closed.